Education
About Us
Working with TipRanks
Follow Us
Paradigm Biopharmaceuticals Ltd. (AU:PAR)
ASX:PAR
PAR Stock Chart & Stats
AU$0.33
-AU$0.03(-5.32%)
At close: 4:00 PM EST
AU$0.33
-AU$0.03(-5.32%)
Day’s Range― - ―
52-Week RangeAU$0.26 - AU$0.66
Previous CloseN/A
Volume3.26M
Average Volume (3M)841.61K
Market Cap
AU$147.84M
Enterprise ValueAU$101.96M
Total Cash (Recent Filing)AU$16.82M
Total Debt (Recent Filing)AU$5.48K
Price to Earnings (P/E)―
Beta3.08
Next Earnings
Feb 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding428,519,170
10 Day Avg. Volume720,106
30 Day Avg. Volume841,610
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)4.53
Price to Sales (P/S)1840.42
P/FCF Ratio-6.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Paradigm Biopharmaceuticals News
PAR FAQ
What was Paradigm Biopharmaceuticals Ltd.’s price range in the past 12 months?
Paradigm Biopharmaceuticals Ltd. lowest share price was AU$0.26 and its highest was AU$0.66 in the past 12 months.
What is Paradigm Biopharmaceuticals Ltd.’s market cap?
Paradigm Biopharmaceuticals Ltd.’s market cap is AU$147.84M.
When is Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date?
Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date is Feb 25, 2026 which is in 46 days.
How were Paradigm Biopharmaceuticals Ltd.’s earnings last quarter?
Paradigm Biopharmaceuticals Ltd. released its earnings results on Aug 29, 2025. The company reported -AU$0.033 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.033.
Is Paradigm Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Paradigm Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Paradigm Biopharmaceuticals Ltd. pay dividends?
Paradigm Biopharmaceuticals Ltd. does not currently pay dividends.
What is Paradigm Biopharmaceuticals Ltd.’s EPS estimate?
Paradigm Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Paradigm Biopharmaceuticals Ltd. have?
Paradigm Biopharmaceuticals Ltd. has 428,519,170 shares outstanding.
What happened to Paradigm Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Paradigm Biopharmaceuticals Ltd. reported an EPS of -AU$0.033 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.509%.
Which hedge fund is a major shareholder of Paradigm Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:PAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Paradigm Biopharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PAR Sentiment 90%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.63%
12-Months-Change
Fundamentals
Return on Equity
-81.03%
Trailing 12-Months
Asset Growth
-11.97%
Trailing 12-Months
Company Description
Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Technical Analysis
Imugene
―
Alterity Therapeutics
―
Pharmaust Limited
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---